{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=inhaled+corticosteroids+%28ICS%29",
    "query": {
      "intervention": "inhaled corticosteroids (ICS)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=inhaled+corticosteroids+%28ICS%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T06:00:54.799Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03622112",
      "title": "A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "AZD7594 DPI 55μg/50μg.",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 99 µg/90 µg",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 198 µg/180 µg",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 396 µg/360 µg once daily.",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 792 µg/720 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7594 once daily.",
          "type": "DRUG"
        },
        {
          "name": "FF 100 µg once daily (open-label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 808,
      "start_date": "2019-01-02",
      "completion_date": "2019-09-30",
      "has_results": true,
      "last_update_posted_date": "2020-11-27",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 21,
      "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Gold River",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03622112"
    },
    {
      "nct_id": "NCT02139644",
      "title": "Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FS MDPI",
          "type": "DRUG"
        },
        {
          "name": "Fp MDPI",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDPI",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "Beclomethasone dipropionate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 787,
      "start_date": "2014-06",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2021-11-12",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 76,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02139644"
    },
    {
      "nct_id": "NCT04184297",
      "title": "Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium and Olodaterol (Tio+Olo)",
          "type": "DRUG"
        },
        {
          "name": "Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 27190,
      "start_date": "2019-11-01",
      "completion_date": "2019-11-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04184297"
    },
    {
      "nct_id": "NCT06596512",
      "title": "Improving the Quality of Care for Asthma Patients at Risk of Exacerbations",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma",
        "Asthma Chronic",
        "Asthma Severe Persistent With Exacerbation",
        "Asthma Moderate Persistent With Exacerbation"
      ],
      "interventions": [
        {
          "name": "PARTICS using a single ICS add on",
          "type": "DRUG"
        },
        {
          "name": "MART",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4100,
      "start_date": "2026-07",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06596512"
    },
    {
      "nct_id": "NCT04450108",
      "title": "Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma",
        "Asthma in Children"
      ],
      "interventions": [
        {
          "name": "Vivatmo pro FeNO Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Bosch Healthcare Solutions GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "7 Years to 80 Years"
      },
      "enrollment_count": 122,
      "start_date": "2020-09-08",
      "completion_date": "2021-04-13",
      "has_results": true,
      "last_update_posted_date": "2022-06-06",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • White Marsh, Maryland + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "White Marsh",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04450108"
    },
    {
      "nct_id": "NCT01017952",
      "title": "A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/GW642444 Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "GW642444 Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1635,
      "start_date": "2009-09-25",
      "completion_date": "2011-10-17",
      "has_results": true,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 89,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tallassee",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01017952"
    },
    {
      "nct_id": "NCT02175771",
      "title": "Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Persistent Asthma"
      ],
      "interventions": [
        {
          "name": "Fp MDPI",
          "type": "DRUG"
        },
        {
          "name": "FS MDPI",
          "type": "DRUG"
        },
        {
          "name": "FLOVENT HFA",
          "type": "DRUG"
        },
        {
          "name": "ADVAIR DISKUS",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 758,
      "start_date": "2014-07",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 101,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175771"
    },
    {
      "nct_id": "NCT03134755",
      "title": "Stress and Treatment Response in Puerto Rican Children With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma in Children"
      ],
      "interventions": [
        {
          "name": "Inhaled corticosteroid (mometasone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "8 Years to 20 Years"
      },
      "enrollment_count": 249,
      "start_date": "2018-05-15",
      "completion_date": "2022-05-18",
      "has_results": false,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03134755"
    },
    {
      "nct_id": "NCT01854047",
      "title": "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "ICS/LABA therapy",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol/albuterol",
          "type": "DRUG"
        },
        {
          "name": "Levosalbutamol/levalbuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 776,
      "start_date": "2013-06",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 50,
      "location_summary": "Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854047"
    },
    {
      "nct_id": "NCT01443845",
      "title": "Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD",
        "COPD Exacerbation",
        "Lung Diseases",
        "Respiratory Disorders",
        "Pulmonary Disease",
        "Chronic Obstructive Lung Diseases",
        "Chronic Obstructive Airway Disease"
      ],
      "interventions": [
        {
          "name": "Roflumilast",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 2354,
      "start_date": "2011-09-30",
      "completion_date": "2016-01-31",
      "has_results": true,
      "last_update_posted_date": "2017-04-13",
      "last_synced_at": "2026-09-27T06:00:54.799Z",
      "location_count": 217,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443845"
    }
  ]
}